<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480166</url>
  </required_header>
  <id_info>
    <org_study_id>33196</org_study_id>
    <nct_id>NCT02480166</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6</brief_title>
  <official_title>Comparative Efficacy of Fixed-dose Combination of Sofosbuvir and Ledipasvir for 8 or 12 Weeks for Chronic Hepatitis C Genotype 6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to describe the efficacy of:

        1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6

        2. 12-week treatment of SOF/LED for all other HCV-6 populations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective of this study is to describe safety, persistency, and tolerability
      of SOF/LED in patients with HCV-6.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained virologic response (SVR) HCV RNA PCR &lt;25 IU/mL 12 weeks post-treatment</measure>
    <time_frame>12 weeks after end of therapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events, adverse events grade 3 and above</measure>
    <time_frame>Day 1 of treatment to 12 weeks post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>PT-NANBH</condition>
  <arm_group>
    <arm_group_label>8 weeks SOF/LED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 weeks SOF/LED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8 weeks SOF/LED</intervention_name>
    <description>Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.</description>
    <arm_group_label>8 weeks SOF/LED</arm_group_label>
    <other_name>Harvoni</other_name>
    <other_name>Solvaldi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 weeks SOF/LED</intervention_name>
    <description>Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.</description>
    <arm_group_label>12 weeks SOF/LED</arm_group_label>
    <other_name>Harvoni</other_name>
    <other_name>Solvaldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age ≥18 years

          2. HCV genotype 6 or indeterminate and later assessed at Screening and confirmed as
             genotype 6

          3. Selected to start on treatment by their treating providers

          4. Willing and able to provide informed consent

          5. Able to comply with dosing instructions for study drug administration and able to
             complete the study schedule of assessments

          6. Females of childbearing potential must have a negative serum pregnancy test at
             Screening and a negative pregnancy test on Baseline

          7. Male subjects and female subjects of childbearing potential who engage in
             heterosexual intercourse must agree to use protocol specified method(s) of
             contraception

          8. Lactating females must agree to discontinue nursing before the study drug is
             administered

        Exclusion Criteria:

          1. Previous recipient of a liver transplant

          2. Co-infection with human immunodeficiency virus (HIV) or hepatitis B (HBV)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mindie H Nguyen, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mindie H Nguyen, MD, MAS</last_name>
    <phone>650-498-5691</phone>
    <email>mindiehn@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akiko Mizuta, BA</last_name>
    <phone>650-498-5691</phone>
    <email>amizuta@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindie H Nguyen, MD, MAS</last_name>
      <phone>650-498-5691</phone>
      <email>mindiehn@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huy N Trinh, MD, AGAF</last_name>
      <phone>408-347-9001</phone>
      <email>htrinh@sjgi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liver and Digestive Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thuan Nguyen, MD</last_name>
      <phone>281-983-0205</phone>
      <email>ttngidoc@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Health Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Son Do, MD</last_name>
      <phone>972-398-0393</phone>
      <email>dotuongson@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 Aug 15;369(7):678-9. doi: 10.1056/NEJMc1307641.</citation>
    <PMID>23944316</PMID>
  </reference>
  <reference>
    <citation>Lam KD, Trinh HN, Do ST, Nguyen TT, Garcia RT, Nguyen T, Phan QQ, Nguyen HA, Nguyen KK, Nguyen LH, Nguyen MH. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology. 2010 Nov;52(5):1573-80. doi: 10.1002/hep.23889.</citation>
    <PMID>21038410</PMID>
  </reference>
  <reference>
    <citation>Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.</citation>
    <PMID>24725238</PMID>
  </reference>
  <reference>
    <citation>Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.</citation>
    <PMID>24725239</PMID>
  </reference>
  <reference>
    <citation>Chao DT, Abe K, Nguyen MH. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther. 2011 Aug;34(3):286-96. doi: 10.1111/j.1365-2036.2011.04714.x. Epub 2011 May 29. Review.</citation>
    <PMID>21623850</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 29, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mindie H. Nguyen</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>hepatitis C, genotype 6</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
